← Blog
Weight Loss

Can You Take GLP-1 Medication If You Are Overweight but Not Obese?

Michael Wright
November 13, 2026
Medically reviewed by
Dr. Stan Saji, PharmD, MBA, RPh

The short answer: Yes... potentially. FDA-approved GLP-1 weight management medications such as Wegovy (semaglutide) and Zepbound (tirzepatide) are indicated for adults with obesity, or adults with overweight who also have at least one weight-related health condition. A clinician still needs to determine whether treatment is appropriate for the individual patient.

Common Eligibility Factors Clinicians Consider

For patients in the overweight range, the presence of a weight-related comorbidity is the factor that most commonly determines eligibility. But it's one consideration among several.

Factor What Clinicians Typically Look For
BMI A BMI of 27 or higher with at least one weight-related comorbidity, or a BMI of 30 or higher regardless of comorbidity
Weight-related comorbidities High blood pressure, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease: any one of these at BMI 27+ typically supports eligibility
Treatment history Prior weight loss attempts, including dietary changes, exercise programs, behavioral interventions, and previous medications
Treatment goals Degree of weight loss sought, metabolic health objectives, and realistic expectations about what GLP-1 therapy can achieve
Age and product indication Wegovy is approved for adults and adolescents aged 12 and older; Zepbound is currently approved for adults only
Contraindications Contraindications and major precautions: Personal or family history of medullary thyroid carcinoma (MTC), MEN2, or a previous serious hypersensitivity reaction to the medication are formal contraindications. Other conditions, including severe gastroparesis, previous pancreatitis, and certain other gastrointestinal or medical conditions, require additional clinical assessment and may make treatment inappropriate.
Overall benefit-risk assessment Weighing clinical benefit against individual health history, comorbidities, concomitant medications, and patient preferences

For overweight patients specifically, the comorbidity requirement deserves attention. A BMI of 27 with well-controlled hypertension generally supports eligibility. A BMI of 27 with no weight-related health conditions generally does not... at least, not under current FDA-approved criteria. That's worth understanding before starting your application process.

Medical History That May Affect Treatment

Several categories of medical history require careful evaluation before starting any GLP-1 medication, regardless of your BMI. None of these are automatic disqualifiers in every case, but all of them require honest disclosure and clinical assessment.

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This is a contraindication across all currently approved GLP-1 weight management medications. GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumor risk based on animal studies; while human relevance hasn't been established, the contraindication applies to both semaglutide and tirzepatide.

History of pancreatitis. GLP-1 medications have been associated with pancreatitis risk, including acute and fatal cases. A prior episode requires careful clinical evaluation before treatment is considered.

Gallbladder disease or history of gallstones. Both rapid weight loss and GLP-1 therapy have been independently associated with increased gallbladder events. Patients with relevant history should discuss this with their clinician before starting.

Gastroparesis or severe gastrointestinal motility disorders. GLP-1 medications slow gastric emptying as part of their mechanism. Patients with existing gastroparesis are generally not appropriate candidates.

Significant renal impairment. GI side effects (particularly vomiting and diarrhea) increase dehydration risk and the potential for acute kidney injury. Renal function is relevant context for the intake evaluation.

History of diabetic retinopathy. Rapid improvement in blood sugar control has been associated with temporary worsening of retinopathy in some patients with type 2 diabetes. Monitoring is recommended for patients with this history.

Pregnancy and breastfeeding require separate discussion with the prescriber. For weight management, Wegovy should be stopped when pregnancy is recognized and at least 2 months before a planned pregnancy. Zepbound should be discontinued when pregnancy is recognized. Breastfeeding recommendations differ by product and formulation, so patients who are breastfeeding or planning to breastfeed should review the specific medication with their clinician.

History of significant eating disorders. The appetite-suppressing effects of GLP-1 medications may complicate recovery in patients with a history of restrictive eating. Individual clinical assessment is especially important in this population.

Medication and Supplement Review

A complete medication list is one of the most important things a patient can bring to a GLP-1 eligibility evaluation. Several categories require specific clinical attention.

Blood sugar-lowering medications. Patients taking insulin or sulfonylureas alongside a GLP-1 medication face an increased risk of hypoglycemia. Dose adjustments to existing diabetes medications are often needed when starting GLP-1 therapy and should always be clinician-directed.

Oral hormonal contraceptives. Tirzepatide's effect on gastric emptying can reduce contraceptive efficacy. The current Zepbound prescribing label advises patients to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase.

Oral medications with narrow therapeutic windows. Slowed gastric emptying can affect the absorption of certain oral drugs: particularly, thyroid medications, anticoagulants, and immunosuppressants where consistent absorption matters. A full medication review is essential for patients on these drugs.

Other GLP-1 medications. Combining a GLP-1 medication with another product from the same class is not recommended, including overlapping brand-name and compounded versions.

Supplements. Supplements that affect blood sugar or metabolic function (including berberine and high-dose chromium) should be disclosed during intake. Their potential interaction with GLP-1 therapy is worth a clinical conversation even when the evidence base is limited.

BMI Is Not the Only Consideration

The BMI thresholds in GLP-1 prescribing guidelines exist because BMI is a practical, widely available screening tool... not because it perfectly captures health risk. BMI doesn't distinguish between fat mass and lean mass. It doesn't account for where fat is distributed in the body, as visceral fat around the abdomen carries meaningfully different metabolic risk than subcutaneous fat. And it can misclassify health status across different body types and ethnic backgrounds in ways that both overstate and understate actual risk.

A patient with a BMI of 28 who carries significant visceral fat, has borderline blood pressure, elevated triglycerides, and a family history of type 2 diabetes may face meaningfully higher metabolic risk than their number suggests, and may be a strong candidate for GLP-1 therapy. A patient with a BMI of 28 and no weight-related health conditions, excellent metabolic markers, and no family history of relevant conditions presents a very different clinical picture.

This is why the eligibility criteria for GLP-1 medications at the overweight BMI threshold specifically require a weight-related comorbidity, the clinical signal that the weight is meaningfully affecting health. BMI gets you to the conversation. The comorbidity, and everything else in the clinical picture, determines whether GLP-1 therapy is the right response.

What Happens During a GLP-1 Eligibility Assessment?

At Lttl, the eligibility process for our weight loss, longevity, and other programs is designed to surface the information a clinician actually needs to make a sound prescribing decision, not to create friction for its own sake.

Step 1: Complete the health intake. The process begins with a comprehensive health questionnaire covering your medical history, current medications and supplements, relevant family history, previous weight loss attempts, and your treatment goals. It takes approximately two minutes. For overweight patients specifically, disclosing any weight-related health conditions (even ones that feel minor or well-controlled) is important, because these comorbidities are often what supports eligibility at a BMI below 30.

Step 2: Licensed clinician review. A licensed clinician reviews your intake individually. This isn't an automated approval process. A real clinician evaluates your eligibility against current clinical criteria, reviews your contraindications and medications, and makes a prescribing decision based on your specific profile. If your intake raises questions, the clinician will follow up before making a determination.

Step 3: Lab work, if needed. Depending on your health history, the clinician may request recent lab work before finalizing a treatment plan. Metabolic panels and other relevant markers help fill in the clinical picture that a questionnaire alone can't fully capture. Recent results from your primary care provider can often be submitted directly.

Step 4: Treatment plan or alternative guidance. If GLP-1 therapy is appropriate for you, your clinician will develop a treatment plan including medication selection, starting dose, and titration schedule. If it isn't appropriate (including if your BMI and comorbidity profile don't meet the clinical criteria), you'll receive a clear explanation and guidance on alternatives where possible.

What to have ready: your current medication list including supplements, recent lab results if available, significant medical history including any diagnosed conditions, and a clear sense of your weight loss and health goals.

Lttl currently offers compounded semaglutide at $89 per month and compounded tirzepatide at $139 per month: both all-inclusive, covering medication, clinician oversight, unlimited care team access, and shipping. Compounded semaglutide and tirzepatide are not FDA-approved and have not been independently evaluated by the FDA for safety, efficacy, or quality.

Frequently Asked Questions

What BMI Do You Need for a GLP-1 Medication?

The FDA-approved clinical criteria for GLP-1 weight management medications include a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Patients who meet either of these criteria may be candidates, though eligibility is ultimately determined through a clinical evaluation, not the number alone.

What Counts as a Weight-Related Comorbidity for GLP-1 Eligibility?

The conditions that most commonly support eligibility at a BMI of 27 include hypertension, type 2 diabetes, dyslipidemia (high cholesterol or triglycerides), obstructive sleep apnea, and cardiovascular disease. A clinician will evaluate whether your specific condition qualifies and whether it is meaningfully connected to your weight. A condition that exists independently of weight (and that wouldn't improve with weight loss) may carry different clinical weight than one that is directly affected by it.

Can I Get a GLP-1 Medication for Overweight Without Seeing a Doctor in Person?

Yes. Telehealth weight management programs, like Lttl's, provide access to licensed clinicians who can evaluate your eligibility and, when appropriate, prescribe GLP-1 medications without requiring an in-person visit. The clinical evaluation is the same: a thorough intake, individual clinician review, and a prescribing decision based on your specific health profile. The difference is where it happens, not whether the clinical standard applies.

I'm Overweight and Have High Blood Pressure. Does That Automatically Qualify Me?

Hypertension is one of the qualifying comorbidities for GLP-1 therapy at a BMI of 27 or higher, so it supports eligibility... but it doesn't guarantee a prescription. Contraindications, current medications, and overall health history are all reviewed as part of the clinical evaluation. The comorbidity is a necessary condition for eligibility at that BMI, not a sufficient one on its own.

What if I Don't Quite Meet the BMI or Comorbidity Criteria?

If you don't meet either the BMI threshold or the comorbidity requirement, GLP-1 medications for weight management are likely not clinically indicated under current guidelines. A clinician will tell you that clearly during the evaluation rather than prescribing anyway. If you're close to the threshold or have borderline metabolic markers, a conversation with a clinician is still worthwhile, as the full clinical picture sometimes supports a different conclusion than the numbers alone suggest. Lifestyle interventions and other treatment options are worth discussing regardless.

Bibliography

  • Novo Nordisk. (2026). Wegovy (semaglutide) injection and tablets: Full prescribing information (Revised March 2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
  • Eli Lilly and Company. (2026). Zepbound (tirzepatide) injection, for subcutaneous use: Full prescribing information (Revised February 2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
  • Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  • Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  • Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boule, N., Boyling, E., Brown, J., Calam, B., Clarke, C., Crowshoe, L., Divalentino, D., Forhan, M., Freedhoff, Y., Gagner, M.,... Wicklum, S. (2020). Obesity in adults: A clinical practice guideline. CMAJ, 192(31), E875-E891. https://www.cmaj.ca/content/192/31/E875
TAGS:
GLP-1 Overweight Not Obese, GLP-1 BMI 27, Weight-Related Comorbidity
Related articles